Thursday, December 8

Flora Growth Completes Construction of Laboratory, Specializing in Prescription Cannabis Formulations


Article content

FORT LAUDERDALE, Fla. & TORONTO — Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today the completion of its new laboratory, specializing in the manufacturing of compound formulations utilizing and utilizing cannabis traditional derivative master formulas. Located in Bogota, Colombia, Flora Lab 4 will become part of Flora’s group of laboratories including existing labs that produce cosmetics, phytotherapeutic products, dietary supplements, and cannabis extraction and transformation.

Article content

“The completion of Flora Lab 4 is an important step in Flora Growth’s progress toward commercializing medicinal cannabis. This lab is built to produce prescription grade medications and manufacture cannabis-based formulations,” said Luis Cor Merchan, Chairman and CEO of Flora Growth “ We look forward to giving access to prescribing doctors in Colombia and more importantly, to patients who stand to benefit from safe, high quality medicinal cannabis.”

Article content

The new laboratory will offer design, development, and manufacturing services of master formulas for third parties, making available to clients its knowledge of cannabis, its professional team, and modern facilities to promote growth in the sector.

Flora Lab 4’s initial prescription formulations have been developed to support the treatment of specific ailments such as social anxiety and acne. The laboratory is waiting for a regulatory inspection by INVIMA to complete certification. Once this step is complete, the new formulations to be available Prescribing doctors in Colombia.

Flora Growth is focused on creating long-term growth within its Life Sciences division through utilizing raw materials from its cannabis cultivation and processing operations in Colombia for applied research initiatives in medical cannabis around the world. The Lab will serve over as the Company’s development, manufacturing, and commercialization of phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of ailments and diseases.

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains ”forward-looking statements,” as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue ,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual 2 Report on F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that in included this release and in Flora’s filings with the SEC. While forward-looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect underlying changes in ass factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005424/en/

Contacts

Investor Relations:
Sean Mansouri, CFA
[email protected]

Public Relations:
Cassandra Dowell
+1 (858) 221-8001
[email protected]

#distro



financialpost.com

Leave a Reply

Your email address will not be published. Required fields are marked *